Acorai

Cover Block

PUBLIC

Name	Acorai
Tagline	Develops non-invasive handheld Acorai Heart Monitor using multi-sensor SAVE system and ML for heart failure pressure monitoring.
Headquarters	Helsingborg, Sweden
Founded	2019
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding Label	Seed (total disclosed ~$9,000,000)

Links

PUBLIC

• Website: https://acorai.com/
• LinkedIn: https://www.linkedin.com/company/acorai

Executive Summary

PUBLIC Acorai is a Swedish medtech startup developing a handheld, non-invasive device to estimate critical cardiac pressures, aiming to reduce the need for invasive catheterization in heart failure management [TechCrunch, January 2024]. The company warrants attention for its technical validation in a large clinical study and its positioning to enter the US market pending regulatory clearance next year. Founded in 2019, Acorai has progressed from a research concept to a device with FDA Breakthrough Designation, supported by a total of approximately $9 million in grants and seed funding [Perplexity Sonar Pro, Unknown]. Its core product, the Acorai Heart Monitor, uses a proprietary multi-sensor system (SAVE) combined with machine learning to provide hemodynamic data, a method clinically tested in over 2,000 patients [Acorai, Unknown]. The founding team brings experience from large device manufacturers and startups, though specific prior roles are not detailed in public sources [Acorai, Unknown]. The business model targets hospital sales for clinician use, with a commercial launch anticipated by 2026 and US entry targeted for the second half of 2025 [TechCrunch, January 2024]. Over the next 12-18 months, key milestones to watch include the completion and publication of its CAPTURE-HF clinical study results, securing US regulatory clearance, and the announcement of initial commercial partnerships or pilot deployments.

Data Accuracy: YELLOW -- Core product and funding claims are company-sourced; clinical study and FDA designation are corroborated by third-party publications. Market size and total funding figure rely on a single secondary source.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Seed (total disclosed ~$9,000,000)

Company Overview

PUBLIC

Acorai is a Swedish medical device company founded in 2019 and headquartered in Helsingborg [Perplexity Sonar Pro, Unknown]. The company was established to develop a non-invasive handheld monitor for heart failure management, a goal that has remained consistent through its early development and funding stages.

The company's public milestones trace a path from initial grant funding to a significant seed round. In 2023, Acorai secured a €2.3 million grant from the European Commission [Acorai, Unknown]. This was followed in January 2024 by a $4 million seed round led by Solardis Health Ventures, which the company described as oversubscribed [TechCrunch, January 2024]. The total capital raised across these and other undisclosed rounds is reported at approximately $9 million [Perplexity Sonar Pro, Unknown]. A key regulatory milestone was receiving FDA Breakthrough Device Designation for its Heart Monitor, though the date of this designation is not specified in public sources [Medical Device Network, Unknown].

Data Accuracy: YELLOW -- Key dates and amounts rely on a single primary source (TechCrunch) and company blog posts; total funding figure is not independently corroborated.

Product and Technology

MIXED The core of Acorai's proposition is a hardware and software system designed to replace an invasive diagnostic procedure with a brief, non-invasive measurement. The Acorai Heart Monitor is a handheld device that uses its patented SAVE Sensor System to estimate intracardiac pressures, specifically pulmonary artery pressure, by placing the unit on a patient's chest for a few minutes [Acorai] [TechCrunch, January 2024]. The company positions the device as a tool to aid in heart failure management for healthcare professionals, not as a standalone diagnostic device [Acorai].

The SAVE system integrates four sensor modalities: seismic, acoustic, visual, and electrical, with machine learning algorithms to interpret the combined signal [Acorai]. The company states the technology has been clinically tested in over 2000 patients [PUBLIC] [Acorai]. Its primary clinical validation effort is the ongoing CAPTURE-HF study, a large-scale global data acquisition study comparing the device's readings against the gold-standard invasive method, right heart catheterization. Enrollment for this study is complete, and positive results from a 1,600-patient cohort were presented in 2025 [Acorai News] [MedTech Innovator, 2025]. The company has received FDA Breakthrough Device Designation for the monitor [Medical Device Network].

Acorai's public timeline targets a commercial launch by 2026, with an initial U.S. market entry planned for the second half of 2025 pending regulatory clearance [PRIVATE] [TechCrunch, January 2024]. The intended initial use case is within in-hospital workflows for patients with suspected or confirmed heart failure [TechCrunch, January 2024].

Data Accuracy: YELLOW -- Product claims are sourced from company materials and one press article; clinical study details are from company announcements and a third-party summary.

Market Research and Opportunity

PUBLIC The market for heart failure management tools is expanding under pressure from rising global prevalence and the high cost of hospital readmissions, creating a clear opening for technologies that can improve clinical decision-making without adding procedural risk.

The total addressable market is anchored by a global patient population of approximately 60 million individuals living with heart failure [Perplexity Sonar Pro]. This figure, while not derived from a specific third-party report, aligns with widely cited epidemiology from organizations like the American Heart Association. The served addressable market for Acorai's initial focus is narrower, targeting the in-hospital workflow for suspected or confirmed heart failure patients [TechCrunch, January 2024]. This includes patients undergoing diagnostic workup or acute decompensation management, a segment where the need for rapid, reliable pressure data is most acute.

Several demand drivers underpin the opportunity. First, the clinical standard for measuring intracardiac pressures, right heart catheterization, is invasive, carries procedural risks, and requires specialized facilities and personnel. A validated non-invasive alternative could expand access to this hemodynamic data. Second, healthcare systems face significant financial penalties for heart failure readmissions, incentivizing tools that help clinicians optimize therapy and discharge planning more effectively. Third, an aging global population is expected to increase the incidence of heart failure, sustaining long-term demand for management solutions.

Acorai's technology also touches adjacent markets for remote patient monitoring and chronic disease management, though the company has publicly pivoted its initial focus to in-hospital use [TechCrunch, January 2024]. Key substitute markets include other non-invasive monitoring technologies, such as implantable pulmonary artery pressure sensors (e.g., CardioMEMS) and echocardiography, though these differ in their mechanism, cost, and application setting.

Regulatory pathways represent a critical macro force. Acorai has received FDA Breakthrough Device Designation, which can streamline the review process for devices that address unmet medical needs [Medical Device Network]. However, achieving regulatory clearance in the US and other key markets remains a prerequisite for commercial launch and a central execution risk. The planned US entry in the second half of 2025 is contingent on this clearance [TechCrunch, January 2024].

Global Heart Failure Patients | 60 | million

The single, widely cited patient population figure underscores the scale of the underlying condition but does not directly translate to a serviceable market for a pre-commercial, clinician-operated device. The more immediate opportunity is defined by the subset of these patients who present to hospitals and would currently be candidates for invasive monitoring.

Data Accuracy: YELLOW -- Market size figure is from a single, unverified source; demand drivers and regulatory status are corroborated by multiple public statements.

Competitive Landscape

MIXED Acorai's competitive position is defined by its attempt to replace a gold-standard invasive procedure with a non-invasive, handheld alternative, a proposition that faces resistance from entrenched clinical workflows and well-funded incumbents.

No named competitors were identified in the captured sources, which limits a direct, point-by-point comparison. The analysis therefore focuses on mapping the broader competitive terrain based on the company's stated target and technology.

• Invasive procedure incumbents. The primary alternative is the right heart catheterization (RHC), an invasive procedure performed in a catheterization lab to directly measure pulmonary artery pressures. This method, while the clinical gold standard, carries procedural risks, requires specialized facilities and personnel, and is costly. Acorai's entire value proposition is built on displacing a portion of these procedures for monitoring and management, not initial diagnosis [Acorai, Unknown].
• Non-invasive monitoring challengers. Several companies are developing less invasive or non-invasive hemodynamic monitoring technologies, though none with the specific multi-sensor (SAVE) approach Acorai describes. This segment includes implantable wireless pressure sensors (e.g., CardioMEMS by Abbott) and external wearable devices focused on other physiological signals. The key differentiator Acorai claims is the combination of seismic, acoustic, visual, and electrical sensing in a single, brief handheld measurement [Acorai, Unknown].
• Adjacent diagnostic substitutes. The competitive set expands to include other tools clinicians use to assess heart failure status, such as echocardiography, blood biomarker tests (e.g., BNP), and physical exam findings. These are often used in combination and represent the established, reimbursed pathways Acorai must integrate into or supplement.

Acorai's most tangible defensible edge today is its proprietary SAVE sensor system and the associated machine learning algorithms trained on clinical data. The company reports clinical testing in over 2,000 patients and the completion of enrollment for its large-scale CAPTURE-HF study [Acorai, Unknown]. This dataset, if it yields strong validation, creates a technical and regulatory moat. The FDA Breakthrough Device Designation is a non-trivial regulatory advantage that can accelerate review and signal clinical need [Medical Device Network, Unknown]. However, this edge is perishable; it depends entirely on the yet-to-be-published full clinical results achieving the accuracy required for clinical adoption and reimbursement.

The company is most exposed on commercial execution and capital. With a total disclosed raise of approximately $9 million, its war chest is modest for the costly path of U.S. FDA clearance, commercial launch, and building a hospital sales force [Perplexity Sonar Pro]. Well-capitalized medtech incumbents with established cardiology sales channels could develop or acquire similar technology, leveraging their existing customer relationships. Furthermore, Acorai's pivot to an in-hospital clinician tool, as reported, means it must now compete for capital equipment budgets and prove workflow integration, a different challenge than remote patient monitoring [TechCrunch, January 2024].

The most plausible 18-month competitive scenario hinges on clinical data and regulatory milestones. If Acorai successfully publishes compelling CAPTURE-HF results in a major cardiology journal and secures FDA clearance on schedule for a late 2025 U.S. entry, it becomes a credible challenger. In this scenario, it could capture early-adopter academic medical centers. The "winner" would be Acorai if it demonstrates superior accuracy and usability data that convinces key opinion leaders. Conversely, the "loser" scenario occurs if clinical data is merely comparable to existing non-invasive surrogates, if regulatory timelines slip significantly, or if a larger player announces a competing non-invasive pressure monitoring product. In that case, Acorai's first-mover advantage and limited funding could become a severe liability.

Data Accuracy: YELLOW -- Competitive mapping is inferred from the company's stated target and technology; no direct competitor names were captured in sources.

Opportunity

PUBLIC

If Acorai can successfully navigate the regulatory path and establish its handheld monitor as a new standard of care in heart failure management, the prize is a central role in a multi-billion dollar global market for non-invasive hemodynamic monitoring.

The headline opportunity is to become the default non-invasive tool for in-hospital pressure monitoring, displacing the current standard of invasive right heart catheterization for routine assessments. This outcome is reachable because the company's core technology has already secured FDA Breakthrough Device Designation, a signal of potential clinical importance, and has been tested in over 2,000 patients according to company claims [Acorai]. The clinical validation underway through the large-scale CAPTURE-HF study aims to provide the peer-reviewed evidence needed for clinical adoption [Acorai News]. The company's strategic pivot to focus on clinician workflows within hospitals, rather than remote patient monitoring, targets the point of highest clinical decision-making and reimbursement [TechCrunch, January 2024].

Growth from a promising device to a category-defining platform hinges on several concrete scenarios. The following table outlines two plausible, high-scale paths.

Scenario	What happens	Catalyst	Why it's plausible
Standard of Care in Heart Failure Wards	The Acorai Heart Monitor becomes a routine part of the admission and monitoring protocol for heart failure patients in major hospitals, reducing catheterization volumes.	Successful completion and publication of the CAPTURE-HF study results demonstrating non-inferiority to catheterization.	The study has enrolled a large patient cohort (1,600 patients) and positive initial results were presented in 2025 [MedTech Innovator, 2025]. The device's non-invasive nature addresses a clear clinical need for safer, faster pressure readings.
Expansion into Adjacent Hemodynamic Monitoring	The SAVE sensor platform is validated for monitoring pressures in other cardiac conditions (e.g., pulmonary hypertension) or in critical care settings (e.g., ICU), expanding the addressable market.	FDA clearance for the initial heart failure indication, providing a regulatory foundation for subsequent 510(k) submissions for new uses.	The multi-modal sensor approach (seismic, acoustic, visual, electrical) is fundamentally designed to capture a broad range of physiological signals, not just a single pressure metric [Acorai]. Platform potential is inherent in the technology architecture.

Compounding success for Acorai would look like a classic data and clinical evidence flywheel. Each new device deployment in a hospital generates proprietary waveform data from the SAVE sensors. This data, anonymized and aggregated, is used to further refine and validate the machine learning algorithms that estimate pressure. Improved algorithm accuracy strengthens clinical evidence, which in turn supports regulatory submissions for new indications and geographies. Stronger evidence facilitates deeper hospital integration and adoption, leading to more deployments and more data. Early signs of this flywheel starting are the progression from initial clinical testing in over 2,000 patients to the structured, global CAPTURE-HF study designed to generate the high-quality data required for market entry [Acorai, Acorai News].

Quantifying the size of the win requires looking at comparable medtech valuations. While no direct public peer exists for a pre-commercial, non-invasive pressure monitor, established players in cardiac monitoring and diagnostics trade at significant multiples. For a scenario where Acorai captures a meaningful portion of the in-hospital monitoring workflow for the estimated 60 million heart failure patients worldwide [Perplexity Sonar Pro], the company's value could approach the low billions of dollars. This is a scenario-based outcome, not a forecast, but it is anchored in the scale of the condition it aims to manage and the premium the market places on medical devices that improve standards of care while reducing procedural risk and cost.

Data Accuracy: YELLOW -- The core opportunity framing relies on company-stated clinical progress and a broad market estimate from a secondary source. The growth scenarios are extrapolated from published study goals and the technology's described capabilities.

Sources

PUBLIC

1. [TechCrunch, January 2024] Heart failure monitoring startup Acorai turns heads | https://techcrunch.com/2024/01/30/acorai-seed/

2. [Perplexity Sonar Pro] Acorai: Swedish Medtech Startup for Non-Invasive Heart Failure Monitoring | https://www.perplexity.ai/

3. [Acorai] Home - Acorai | https://acorai.com/

4. [Acorai] Product - Acorai | https://acorai.com/product/

5. [Acorai] Heart Failure start-up, Acorai, secures €2.3m grant funding from the European Commission | https://acorai.com/redefining-heart-failure/heart-failure-start-up-acorai-secures-e2-3m-grant-funding-from-the-european-commission/

6. [Acorai News] Heart Failure start-up, Acorai, closes oversubscribed $4m funding round | https://acorai.com/acorai-news/heart-failure-start-up-acorai-closes-oversubscribed-4m-funding-round/

7. [Medical Device Network] Acorai receives FDA Breakthrough Device Designation | https://www.medicaldevice-network.com/

8. [MedTech Innovator, 2025] ACORAI Presents Positive Results in 1,600-Patient CAPTURE-HF Study | https://medtechinnovator.org/acorai-presents-positive-results-in-1600-patient-capture-hf-study-for-its-ai-powered-non-invasive-multi-sensor-platform-for-improved-heart-failure-patient-management/